Viromed Medical AG Seeks Particular Approval for Chilly Plasma Machine for the Prevention of Ventilator-Related Pneumonia (VAP)

Focused use of the antimicrobial impact of chilly plasma past wound remedy

Use of chilly plasma might revolutionize the remedy of VAP and considerably scale back mortality

Aiming for fast particular approval for personal system in Germany and USA by 2025

PINNEBERG, Germany — Viromed Medical AG (ISIN: DE000A3MQR65; “Viromed”) is launching a second pioneering research on the usage of chilly plasma for the prevention of ventilator-associated pneumonia (VAP). The research, underneath the scientific course of Prof. Dr. Hortense Slevogt from the Hannover Medical Faculty (MHH) and two different world-renowned institutes, goals to acquire fast particular approval for the PulmoPlas system developed by Viromed for this revolutionary safety measure in Germany and the USA.

Article content material

The additional growth and standardization of chilly plasma know-how to be used in study-relevant cell cultures and later additionally within the human lung comes from relyon plasma GmbH, an entirely owned subsidiary of TDK Electronics AG. As a associate of Viromed, relyon plasma will set up the prototypes for the applying and make sure the standardized era of chilly plasma in addition to its characterization and consistency within the trial.

The exploitation rights are held by Viromed Medical AG.

VAP is a frequent and critical complication in mechanically ventilated sufferers. It happens in sufferers who’re invasively mechanically ventilated for a minimum of 48 hours. Research present that VAP happens in 23 to 36 p.c of mechanically ventilated sufferers and is related to extended air flow time and longer stays within the intensive care unit and hospital. The estimated mortality fee is 10 to 13 p.c. In Germany alone, there have been round 486,000 mechanically ventilated intensive care sufferers in 2023 and lots of 1000’s of deaths, with a powerful upward pattern. Many hundreds of thousands of sufferers worldwide are mechanically ventilated yearly. The usage of chilly plasma in opposition to VAP would due to this fact have the potential to avoid wasting a whole lot of 1000’s of lives yearly.

Uwe Perbandt, CEO of Viromed Medical AG: “The usage of chilly plasma has already confirmed very profitable within the remedy of difficult-to-heal wounds. Our imaginative and prescient is to make use of the antimicrobial impact in different areas of software the place remedy with typical strategies results in unsatisfactory outcomes. If a number of hundred thousand sufferers die from VAP yearly, that is unacceptable. As a primary mover, we’re due to this fact systematically driving ahead the related analysis and striving to acquire particular approval for our PulmoPlas system as rapidly as potential, as we see an pressing medical want for a greater resolution to the VAP drawback. On the identical time, we’re tapping into a pretty market section, as the worldwide marketplace for mechanical air flow is predicted to see stable progress averaging 8.2% per yr till 2032 as a result of improve in persistent respiratory ailments.”

Since October 2023, the MHH, in cooperation with Viromed Medical AG, has been investigating the security profile of the usage of chilly plasma in bacterial infections of the respiratory tract utilizing fashions of the respiratory mucosa. Specifically, the main target is on the potential of chilly plasma to kill micro organism which have contaminated the epithelium. In parallel, probably related inflammatory reactions, potential adjustments in cell differentiation, cell demise, DNA injury in addition to the therapeutic dose and the time window of software are being investigated. With a view to optimize the effectiveness of various plasma compositions, their effectiveness in reference to cell injury might be investigated differentially. Attributable to promising preliminary outcomes which have proven no damaging impact on the airway epithelium, a second research is now beginning in parallel, which was initially deliberate for mid-2025. This may develop the investigation of the security profile of chilly plasma on alveolar epithelium, making an allowance for mechanical shear forces that act on the alveolar mucosa throughout respiration. As well as, the potential and security of chilly plasma to kill micro organism utilized to precision-cut lung slices (PCLS) might be examined.

Article content material

Prof. Dr. Hortense Slevogt, Clinic for Pneumology and Infectiology, MHH: “Ventilator-associated pneumonia not solely has a excessive mortality fee, additionally it is a normal burden on the healthcare system attributable to elevated antibiotic consumption, longer affected person stays and better remedy prices. The growing antibiotic resistance of pathogens additionally makes new, non-antibiotic approaches urgently obligatory. If the optimistic preliminary outcomes of our research proceed to be confirmed and the security of chilly bodily plasma within the human lung is established, chilly plasma has the potential to revolutionize the remedy of ventilated sufferers.”

About Viromed Medical AG:

Viromed Medical AG has a broad buyer base within the DACH area, together with numerous DAX firms, e.g. Volkswagen and Lufthansa, in addition to federal states and numerous federal ministries, 1,100 hospitals, 7,000 pharmacies, and 17,000 medical practices.